Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.8B
112M shares
52-week range
$15.96 – $34.72
47% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
ADRC
P/S (TTM)
6.2
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
www.zailaboratory.comNo one on the platform currently holds ZLAB.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 14,300 | $269.0K |
No one on the platform has traded ZLAB yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 15.3% | 56.5% | ||||
| Profit Margin % | -38.1% | -184.5% | ||||
| Free Cash Flow Margin % | -35.7% | -151.7% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $427M | -7.3% | $-2.23 | $-2.43–$-2.01 | — | 6 |
| 2027 | $517M | +21.0% | $-2.13 | $-2.26–$-2.00 | — | 6 |
| 2028 | $703M | +35.9% | $-1.43 | $-2.42–$-0.73 | — | 5 |
| 2029 | $966M | +37.4% | $-0.20 | $-0.25–$-0.17 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $-0.68 | $-0.46 | +32.3% |
| 2026-05-07 | $-0.53 | $-0.46 | +12.6% |
| 2026-02-26 | $-0.44 | $-0.46 | -4.5% |
| 2025-11-06 | $-0.28 | $-0.33 | -17.9% |
| 2025-08-07 | $-0.37 | $-0.37 | +0.0% |
| 2025-05-08 | $-0.50 | $-0.45 | +10.0% |
| 2025-02-27 | $-0.61 | $-0.80 | -31.1% |
| 2024-11-12 | $-0.75 |
| $-0.42 |
| +44.0% |
| +0.00% |
| $6.3B |
| — |
| IDYAIDEAYA Biosciences, Inc. | $37.66 | -0.97% | $3.6B | — |
| IRONDisc Medicine, Inc. | $67.30 | -2.35% | $2.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
$ZLAB why do I keep buying this undervalued and underfollowed equity and it keeps going up? Why???!!!
View on StockTwits ↗$ZLAB Gobbled a few. High conviction and high reward
View on StockTwits ↗$ZLAB Adding on pops. At these prices its free money
View on StockTwits ↗$ZLAB @Pika_Capital is correct on the 3-5x multiplier: wall street is mispricing Zai Lab as a legacy licensing boutique while ignoring 8 commercialized assets (including KarXT, TIVDAK, and VYVGART), a proprietary DLL3-ADC pipeline with FDA Fast Track status heading to Phase 3, and $717M+ in cash runway backing an inevitable re-rate!
View on StockTwits ↗
$ZLAB good timing getting back in 😂
View on StockTwits ↗
$ZLAB New PDUFA Date 2026-11-30 Zai Lab Ltd Link: https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm Calendar: http://www.fdatracker.com/fda-calendar/
View on StockTwits ↗$ZLAB got back in at $20 after selling in $30s while back. This can be easy 3-5x if they execute on the pipeline and commercial side
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-8-6-zai-lab-limited-stock/ $ZLAB Zai Lab Earnings Transcript
View on StockTwits ↗
$ZLAB Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.50 down -25.00% YoY • Reported revenue of $106.31M down -3.33% YoY
View on StockTwits ↗
$ZLAB FDA granting Orphan Drug Designation for zoci is a meaningful step forward. DLL3-targeting ADCs are targeting a difficult cancer area with limited treatment options, and this adds more validation to Zai Lab’s pipeline potential.
View on StockTwits ↗
$ALM $PRME $SONY $ZLAB $CF What is going up today in a down market outlook? MATERIALS and HEALTHCARE. Set an alert then stop out....good to all traders everywhere. 100%--->🦬
View on StockTwits ↗
$ZLAB Great day here, monster comeback on the way
View on StockTwits ↗
$ZLAB TIVDAK approved in China yesterday. Yet another drug with $300M+ potential in the commercial offering. Nobody cares! At some point the money will do the talking, and the rise will be f*** meteoric
View on StockTwits ↗
$ZLAB Share Price: $16.64 Contract Selected: Dec 18, 2026 $20 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.75 – $0.92 Potential Upside: 68% ROI Time to Expiration: 195 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.